+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension

Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension

Plos One 8(6): E63504

A potential role for coagulation factors in pulmonary arterial hypertension has been recently described, but the mechanism of action is currently not known. Here, we investigated the interactions between thrombin and the nitric oxide-cGMP pathway in pulmonary endothelial cells and experimental pulmonary hypertension. Chronic treatment with the selective thrombin inhibitor melagatran (0.9 mg/kg daily via implanted minipumps) reduced right ventricular hypertrophy in the rat monocrotaline model of experimental pulmonary hypertension. In vitro, thrombin was found to have biphasic effects on key regulators of the nitric oxide-cGMP pathway in endothelial cells (HUVECs). Acute thrombin stimulation led to increased expression of the cGMP-elevating factors endothelial nitric oxide synthase (eNOS) and soluble guanylate cyclase (sGC) subunits, leading to increased cGMP levels. By contrast, prolonged exposition of pulmonary endothelial cells to thrombin revealed a characteristic pattern of differential expression of the key regulators of the nitric oxide-cGMP pathway, in which specifically the factors contributing to cGMP elevation (eNOS and sGC) were reduced and the cGMP-hydrolyzing PDE5 was elevated (qPCR and Western blot). In line with the differential expression of key regulators of the nitric oxide-cGMP pathway, a reduction of cGMP by prolonged thrombin stimulation was found. The effects of prolonged thrombin exposure were confirmed in endothelial cells of pulmonary origin (HPAECs and HPMECs). Similar effects could be induced by activation of protease-activated receptor-1 (PAR-1). These findings suggest a link between thrombin generation and cGMP depletion in lung endothelial cells through negative regulation of the nitric oxide-cGMP pathway, possibly mediated via PAR-1, which could be of relevance in pulmonary arterial hypertension.

(PDF emailed within 0-6 h: $19.90)

Accession: 056573678

Download citation: RISBibTeXText

PMID: 23785394

DOI: 10.1371/journal.pone.0063504

Related references

Regulation of the nitric oxide synthase-nitric oxide-cGMP pathway in rat mesenteric endothelial cells. Journal of Applied Physiology 91(6): 2553-2560, 2001

The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clinics in Chest Medicine 28(1): 143-67, Ix, 2007

cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. Circulation Research 76(2): 199-208, 1995

Nitric oxide-cGMP-protein kinase G pathway contributes to cardioprotective effects of ATP-sensitive K+ channels in rat hearts. Korean Journal of Physiology & Pharmacology 8(2): 95-100, April, 2004

Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arteriosclerosis, Thrombosis, and Vascular Biology 23(8): 1345-1351, 2003

Nitric oxide donor, NOC7, reveals dose dependently and cGMP pathway independently biphasic effects on contractile force of isolated rat heart after global ischemia. International Journal of Clinical and Experimental Pathology 8(4): 3843-3849, 2016

Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. American Journal of Physiology. Lung Cellular and Molecular Physiology 289(5): L798-L806, 2005

Mesenteric endothelial cells Characterization of the nitric oxide -cGMP pathway and evidence for differential regulation of inducible NO synthase. Circulation 92(8 SUPPL ): I109, 1995

Nitric oxide reduces T lymphocyte adhesion to human brain microvessel endothelial cells via a cGMP-dependent pathway. European Journal of Pharmacology 514(2-3): 91-98, 2005

Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Experimental & Molecular Medicine 37(6): 588-600, 2006

The antihypertensive hybrid drug urapidil stimulates cGMP generation in bovine endothelial cells probably by the nitric-oxide pathway. Naunyn-Schmiedeberg's Archives of Pharmacology 354(4 SUPPL 1): R46, 1996

Simulated microgravity promotes nitric oxide-supported angiogenesis via the iNOS-cGMP-PKG pathway in macrovascular endothelial cells. Febs Letters 584(15): 3415-3423, 2010

Sepiapterin improves angiogenesis of pulmonary artery endothelial cells with in utero pulmonary hypertension by recoupling endothelial nitric oxide synthase. American Journal of Physiology. Lung Cellular and Molecular Physiology 301(3): L334-L345, 2011

Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radical Biology & Medicine 35(4): 381-396, August 15, 2003